HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Trial Details

NCT ID
NCT06769425
Phase
PHASE1
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • HS-10502 + NHA
  • HS-10502 + HS-20093
  • HS-10502+ Apatinib
  • HS-10502 + HS-20089
  • HS-10502 + Platinum + Bevacizumab
  • HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Males or females aged 18 years or older (≥18 years).
  • Patients diagnosed with pathologically confirmed advanced solid tumors.
  • Subjects have at least one target lesion as assessed per the RECIST 1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →